用英夫利昔单抗治疗的强直性脊柱炎患者白癜风病情改善。
Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab.
作者信息
Simón J-Abraham, Burgos-Vargas Rubén
机构信息
Medical Research Centre, UMAE-Yucatán, IMSS, Department of Internal Medicine, CEM Hospital, Faculty of Medicine, Universidad Nacional Autónoma de México, México, Mexico.
出版信息
Dermatology. 2008;216(3):234-5. doi: 10.1159/000112932. Epub 2008 Jan 9.
Ankylosing spondylitis (AS) is a disabling disease affecting the enthesis and joints of the spine and peripheral sites. Tumour necrosis factor alpha (TNF-alpha) is a proinflammatory mediator which plays a significant role in the pathogenesis of AS. Infliximab (a chimeric monoclonal antibody which blocks the activity of TNF-alpha) is one of the most effective therapies of AS thus far. Vitiligo is a depigmenting disorder of the skin of unknown aetiology affecting 0.5-1% of the population. Here we describe the effect of infliximab on vitiligo in a patient with AS.
强直性脊柱炎（AS）是一种致残性疾病，会影响脊柱及外周部位的附着点和关节。肿瘤坏死因子α（TNF-α）是一种促炎介质，在AS的发病机制中起重要作用。英夫利昔单抗（一种阻断TNF-α活性的嵌合单克隆抗体）是迄今为止治疗AS最有效的疗法之一。白癜风是一种病因不明的皮肤色素脱失性疾病，影响着0.5%至1%的人口。在此，我们描述了英夫利昔单抗对一名AS患者白癜风的疗效。
Zotero 插件